Pilot Study of Redirected Autologous T Cells Transduced to Express A CD20-Specific Chimeric Immunoreceptor in Patient With Chemotherapy Resistant or Refractory CD20+ Leukemia and Lymphoma

Trial Profile

Pilot Study of Redirected Autologous T Cells Transduced to Express A CD20-Specific Chimeric Immunoreceptor in Patient With Chemotherapy Resistant or Refractory CD20+ Leukemia and Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Oct 2015

At a glance

  • Drugs Anti-CD20-CAR-transduced T cells (Primary)
  • Indications Acute lymphoblastic leukaemia; B cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Oct 2015 According to a Cellular Biomedicine Group media release, data from this study will be presented at the 4th International Conference on Translational Medicine 2015.
    • 28 Sep 2015 According to ClinicalTrials.gov record, the phase has been changed from I to I/II. Treatment table has been amended and the subjects age has changed to 18-90 yrs.
    • 28 Sep 2015 Planned number of patients changed from 10 to 50, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top